Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference

SMi Group18 - 20 November 2019, London, UK.
Senior expert from iVeena is set to present at SMi's 3rd Annual Ophthalmic Drugs 3 Day Conference. Europe's leading Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

In the run up to the conference, SMi Group caught up with Mike Burr, Vice President of Product Developmentat iVeena, to discuss his upcoming presentation and his thoughts on the current challenges and opportunities in Ophthalmic Drug development.

A snapshot of Mike Burr's interview

Q. The ophthalmic novel drug delivery market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?
A. "For decades now there has been research in both academia and industry into longer term (beyond one day) sustained delivery technologies for direct ocular applications with minimal translation into commercial products. Regulatory approvals by the FDA in the last year in the post-cataract space for treatments intended to replace daily anti-inflammatory eye drops is very exciting. There is also a robust pipeline of sustained delivery glaucoma therapies which could provide chronic IOP lowering capabilities in the near term."

Q. What do you personally see as the greatest challenge to overcome in ophthalmic drug delivery at the moment?
A. "Now that we are seeing the commercialisation of small molecule sustained release products, with hopefully more to come in the near term, the next frontier is in biologics. Large molecule stability for controlled release applications is a tough one."

The full speaker interview and more content including the latest brochure and past attendees can be found in the DOWNLOADS section on the website at www.ophthalmicdrugs.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...